ACAD
Price
$20.95
Change
-$0.29 (-1.37%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
3.51B
27 days until earnings call
SAGE
Price
$9.20
Change
+$0.12 (+1.32%)
Updated
Jul 3, 02:00 PM (EDT)
Capitalization
576.12M
33 days until earnings call
Interact to see
Advertisement

ACAD vs SAGE

Header iconACAD vs SAGE Comparison
Open Charts ACAD vs SAGEBanner chart's image
ACADIA Pharmaceuticals
Price$20.95
Change-$0.29 (-1.37%)
Volume$170.47K
Capitalization3.51B
Sage Therapeutics
Price$9.20
Change+$0.12 (+1.32%)
Volume$45.27K
Capitalization576.12M
ACAD vs SAGE Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. SAGE commentary
Jul 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and SAGE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 04, 2025
Stock price -- (ACAD: $21.23 vs. SAGE: $9.09)
Brand notoriety: ACAD and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 91% vs. SAGE: 86%
Market capitalization -- ACAD: $3.55B vs. SAGE: $576.12M
ACAD [@Biotechnology] is valued at $3.55B. SAGE’s [@Biotechnology] market capitalization is $576.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileSAGE’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • SAGE’s FA Score: 1 green, 4 red.
According to our system of comparison, ACAD is a better buy in the long-term than SAGE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 3 TA indicator(s) are bullish while SAGE’s TA Score has 6 bullish TA indicator(s).

  • ACAD’s TA Score: 3 bullish, 5 bearish.
  • SAGE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SAGE is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -5.64% price change this week, while SAGE (@Biotechnology) price change was -1.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.15%. For the same industry, the average monthly price growth was +33.42%, and the average quarterly price growth was +4.05%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

SAGE is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Biotechnology (+7.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.51B) has a higher market cap than SAGE($576M). SAGE YTD gains are higher at: 67.403 vs. ACAD (14.169). ACAD has higher annual earnings (EBITDA): 102M vs. SAGE (-358.98M). ACAD has more cash in the bank: 682M vs. SAGE (424M). SAGE has less debt than ACAD: SAGE (11.9M) vs ACAD (56M). ACAD has higher revenues than SAGE: ACAD (996M) vs SAGE (47.4M).
ACADSAGEACAD / SAGE
Capitalization3.51B576M609%
EBITDA102M-358.98M-28%
Gain YTD14.16967.40321%
P/E Ratio15.29N/A-
Revenue996M47.4M2,101%
Total Cash682M424M161%
Total Debt56M11.9M471%
FUNDAMENTALS RATINGS
ACAD vs SAGE: Fundamental Ratings
ACAD
SAGE
OUTLOOK RATING
1..100
5229
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
2697
PRICE GROWTH RATING
1..100
4438
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAGE's Valuation (33) in the Pharmaceuticals Other industry is in the same range as ACAD (63) in the Biotechnology industry. This means that SAGE’s stock grew similarly to ACAD’s over the last 12 months.

SAGE's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ACAD (100) in the Biotechnology industry. This means that SAGE’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (26) in the Biotechnology industry is significantly better than the same rating for SAGE (97) in the Pharmaceuticals Other industry. This means that ACAD’s stock grew significantly faster than SAGE’s over the last 12 months.

SAGE's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as ACAD (44) in the Biotechnology industry. This means that SAGE’s stock grew similarly to ACAD’s over the last 12 months.

SAGE's P/E Growth Rating (98) in the Pharmaceuticals Other industry is in the same range as ACAD (100) in the Biotechnology industry. This means that SAGE’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADSAGE
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 16 days ago
73%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCRIX14.250.02
+0.14%
NYLI CBRE Global Infrastructure Class I
MSFBX34.84N/A
N/A
Morgan Stanley Inst Global Franchise A
GABTX24.33N/A
N/A
Gabelli Global Content & Connect AAA
VFTNX42.83N/A
N/A
Vanguard FTSE Social Index I
PISOX15.23N/A
N/A
Columbia Pyrford International Stk Ins 2

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with INZY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-1.37%
INZY - ACAD
50%
Loosely correlated
N/A
AURA - ACAD
44%
Loosely correlated
+1.55%
CRSP - ACAD
42%
Loosely correlated
+0.97%
STTK - ACAD
39%
Loosely correlated
-1.61%
PGEN - ACAD
39%
Loosely correlated
+0.62%
More